C. Clercx
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
C. Clercx has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Dominique Peeters
Department of Veterinary Clinical Sciences, Faculty of Veterinary Medicine, University of Liège, Sart-Tilman B44, 4000 Liège, Belgium
3 shared publications A Hamaide
1 shared publicationA Thiry
1 shared publicationA. Gabriel
Department of Small Animal Clinical Sciences, Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium
1 shared publication- Alexander James German
Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK
1 shared publication F Snaps
1 shared publication
Latest Publications
- 14 October 2010
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 34 (4) , 322-331
Lack of efficacy of low‐dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs
Aldosterone plays an important role in the pathophysiology of heart failure. Aldosterone receptor blockade has been shown to reduce morbidity and mortality in human patients with advanced congestive left ventricular heart failure. This study was designed to assess the efficacy and tolerance of long-term low-dose spironolactone when added to conventional heart failure treatment in dogs with advanced heart failure. Eighteen client-owned dogs with advanced congestive heart failure due to either degenerative valve disease (n=11) or dilated cardiomyopathy (n=7) were included in this prospective, placebo-controlled, double-blinded, randomized clinical study. After initial stabilization including furosemide, angiotensin-converting enzyme inhibitors, pimobendan and digoxin, spironolactone at a median dose of 0.52 mg/kg (range 0.49-0.8 mg/kg) once daily (n=9) or placebo (n=9) was added to the treatment, and the dogs were reassessed 3 and 6 months later. Clinical scoring, echocardiography, electrocardiogram, systolic blood pressure measurement, thoracic radiography, sodium, potassium, urea, creatinine, alanine aminotransferase, aldosterone and aminoterminal atrial natriuretic propeptide were assessed at baseline, 3 and 6 months. Survival times were not significantly different between the two treatment groups. Spironolactone was well tolerated when combined with conventional heart failure treatment.Journal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tFLWINinfo:eu-repo/semantics/publishe
- 14 October 2010
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 34 (4) , 322-331
Lack of efficacy of low‐dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs
Aldosterone plays an important role in the pathophysiology of heart failure. Aldosterone receptor blockade has been shown to reduce morbidity and mortality in human patients with advanced congestive left ventricular heart failure. This study was designed to assess the efficacy and tolerance of long-term low-dose spironolactone when added to conventional heart failure treatment in dogs with advanced heart failure. Eighteen client-owned dogs with advanced congestive heart failure due to either degenerative valve disease (n=11) or dilated cardiomyopathy (n=7) were included in this prospective, placebo-controlled, double-blinded, randomized clinical study. After initial stabilization including furosemide, angiotensin-converting enzyme inhibitors, pimobendan and digoxin, spironolactone at a median dose of 0.52 mg/kg (range 0.49-0.8 mg/kg) once daily (n=9) or placebo (n=9) was added to the treatment, and the dogs were reassessed 3 and 6 months later. Clinical scoring, echocardiography, electrocardiogram, systolic blood pressure measurement, thoracic radiography, sodium, potassium, urea, creatinine, alanine aminotransferase, aldosterone and aminoterminal atrial natriuretic propeptide were assessed at baseline, 3 and 6 months. Survival times were not significantly different between the two treatment groups. Spironolactone was well tolerated when combined with conventional heart failure treatment.Journal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tFLWINinfo:eu-repo/semantics/publishe
- 25 May 2006
- Published by Wiley in Journal of Small Animal Practice
- Vol. 47 (6) , 344-348
Suspected drug-induced destructive cholangitis in a young dog
- 25 May 2006
- Published by Wiley in Journal of Small Animal Practice
- Vol. 47 (6) , 344-348
Suspected drug-induced destructive cholangitis in a young dog
- 1 January 2003
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 17 (6) , 843-849
Rhinitis/Bronchopneumonia Syndrome in Irish Wolfhounds
- 1 January 2003
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 17 (6) , 843-849
Rhinitis/Bronchopneumonia Syndrome in Irish Wolfhounds